Health
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 – StreetInsider.com
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors exposed to prior lines…
April 10, 2021 8:30 AM EDT
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premiumhere.
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition
Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742
Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter…
-
General21 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
General19 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News24 hours agoBoat crash in Helensvale on the Gold Coast leaves man with life-threatening burns and another one injured
-
Noosa News23 hours agoBrisbane bands unite to help bassist’s cancer fight